Pranjay Sadashiv Patil, a first year M.Pharm student, presented on documentation in pharmaceutical quality assurance. Documentation defines a system to minimize risks from misinterpretation or errors in oral communication. It includes specifications, test procedures, distribution records, and electronic data handling. Specifications provide parameters and limits for materials, equipment, and products. Test procedures must validate compliance to the end of shelf life. Controlled documents require approval and management of changes, while uncontrolled copies are for reference with a watermark.
1. • PRESENTD BY :-
• PATIL PRANJAY SADASHIV.
• FIRST YEAR M.PHARM.
• DEPARTMENT OF QUALITY ASSURANCE.
H. R. Patel Institute of Pharmaceutical Education
and Research, Shirpur
3. INTRODUCTION
Documentation is an integral part of
good manufacturing practices .It defines a
system of information and control so that risks
so inherent in ministerpretation and /or error
in oral communication are minimized.
Information on when,where,who,why,& how
to complete tasks
4. SPECIFICATION
specification may be defined as a set
of parameters along with their acceptance
limits.expected to be met by a particular
material, piece of equipment or any such
object. In case of pharmaceutical products , we
need specification for active and inactive
starting material.
5. TYPES OF SPECIFICATION
1) Specification for active and inactive starting
material
2) Secification for packing material
3) Specification for Intermediate and Bulk
product
4) Specification for Finished Product
6. 1)SPECIFICATION FOR ACTIVE AND INACTIVE STARTING
MATERIAL
i. Name of the material
ii. Code number refernce
iii. Name of approved supplier and original manufacturer
iv. Direction for sampling and testing or refernce to the procedure
v. Storage condition and safety precaution if any
7. 2)SPECIFICATION FOR PACKING MATERIAL
i. Name of material
ii. Code number reference
iii. Sampling instruction
iv. Storage condition
v. Frequency of re-examination of stored components
8. 3) SPECIFICATION FOR INTERMEDIAT AND BULK PRODUCT
i. Specification for intermediat and bulk product should
available if this are purches for dispatch are use in the
evaluation of the finished product
ii. This specification should be similiar to starting material or
finished products as applicable
9. 4) SPECIFICATION FOR FINISHED PRODUCT
i. Name of the product
ii. Code number reference
iii. Names of the active ingredient
iv. The formula or refence to the formula
v. Shelf life
vi. The qualitative and quatitative requirments with
acceptances limits
10. TEST PROCEDURE
Test procedure must be described
in a sufficiently detailed manner to enable
any official laboratory to verify compliance of
the medicinal product upto the end of shelf
life. controle method must be validated in
accordance with the note for guidance.
11. CONTINUE..
The test procedure may use either an official refernce
substance (europian pharmacopeia ,national pharmacopeia
,WHO).
Accepte for those official included in the europian
pharmacopeia eg.sterility test.
12. DISTRIBUTION RECORDS
Distribution records shall contain the name and strength of
the product and description of the dosage form, name and
address of the consignee, date and quality shipped, and lot
or control number of the drug product. For compressed
medical gas products, distribution records are not required to
contain lot or control numbers.
13. Distribution records include a wide range of
documentation such as invoices, bills of
lading, customers’ receipts, internal
warehouse storage and inventory records.
14. It is a software based laboratory
and information management system that
offers a set of key features that helps
supporting modern laboratory’s operations.
Electronic data hadling is replace the
traditional paper-based data collection
methodology to streamline data collection .
16. ADVANTAGES ELECTRONIC DATA CONTROL
1. Faster data transfer
2. Instant data access by the staff
3. Reduced queries
4. Data can be categorized and indexing is possible
5. Decision point can be reached more quickly, this
will save both time and money
17. DISADVANTAGES OF EDC
1. Installation of software in each PC which is costlier
2. Availability of Internet connections in remote areas
where trial is being conducted
3. Data security is a major problem if public internet is
being used
4. Regular validation of electronic devices
5. Regulatory compliance
19. CONTROL DOCUMENT
Each manufacturer shall establish and maintain procedure
to control all document that are required by this part. The
procedure shall provide for the following.
a) Document aprroval and distribution
b) Document changes
20. DOCUMENT APPROVAL AND DISTRTBUTION
Each manufacturer shall designate an individual
to review for adequacy and approve prior to
issuance all document established to meet the
requirement of this part.
The approval, including the data and signature of
the individual approving the document ,shall be
documented.
21. DOCUMENT CHANGES
Changes to document shall be reviewed
and approved by an individual in the same
function or organization that performed the
original review and approval.
Approved changes shall be communicated
to the appropriate personnel in a timely
manner.
22. UNCONTROLLED DOCUMENT
Uncontrolled copy shall be
prepared by photocopy of master copy with
stamping of “ UNCOTROLLED COPY” in red
colour and signed/ dated by QA on each
page of the document at center on the
matter .
23. CONTINUE
Uncontrolled copy shall be distributed on
need as a reference copy for external
regulators and concerns .
24. REFRANCE..
1) Pharmaceutical Quality Assurance by Manohar
A. Potdar published by Nirali prakashan 5th
edition 2016
2) Asian Journal of Pharmaceutical and Clinical
Research by M.N.Raviteja & N.Vishal Gupta
Vol 6, Suppl 2, 2013
3) Pharmaceutical Quality Assurance and
Management by K P Bhusari , U D Shihari and D
C Goupale published Nirali prakashan 2nd
edition 2014